Anebulo Pharmaceuticals (ANEB) investor relations material

Executive summary

• Focused on developing selonabant, a cannabinoid receptor antagonist, for cannabis-induced toxicity, prioritizing pediatric IV formulation due to unmet medical need and regulatory feedback.

• Initiated Phase 1 single ascending dose (SAD) study of IV selonabant for acute cannabis-induced toxicity in children, with FDA clearance and NIDA grant support; ongoing observational study in emergency departments.

• No product revenue to date; operations funded by equity raises, grants, and a loan facility.

• Board approved a proposed reverse stock split as part of a potential going private transaction; process impacted by government shutdown and SEC delays.

Financial highlights

• Net loss for the quarter ended September 30, 2025 was $2.16 million, compared to $2.20 million for the same quarter last year; Q1 FY2026 net loss was $2.2 million on $2.3 million in expenses.

• Operating expenses decreased to $2.26 million from $2.41 million year-over-year, driven by lower R&D costs.

• Cash and cash equivalents were $10.4 million as of September 30, 2025, with access to an additional $3.0 million via a loan agreement.

• No revenue recognized; grant income of $809,991 recognized in Q1 FY2026, down from $245,000 year-over-year.

Outlook and guidance

• Cash and equivalents, plus available loan facility, expected to fund operations for at least 12 months from the report date.

• Ongoing focus on developing selonabant IV for pediatric cannabis toxicity, with support from NIDA and collaboration with FDA.

• Anticipates continued operating losses and need for additional capital to advance clinical programs; R&D expenses expected to increase as clinical studies progress.

• Board expects to provide further updates on strategic alternatives and the reverse stock split by year-end.